Details for New Drug Application (NDA): 208231
✉ Email this page to a colleague
NDA 208231 describes ARSENIC TRIOXIDE, which is a drug marketed by Amneal, Amring Pharms, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Ingenus Pharms Llc, Nexus, Orbicular, Penn Life, Sandoz, and Zydus Pharms, and is included in eleven NDAs. It is available from fifteen suppliers. Additional details are available on the ARSENIC TRIOXIDE profile page.
The generic ingredient in ARSENIC TRIOXIDE is arsenic trioxide. There are five drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the arsenic trioxide profile page.
The generic ingredient in ARSENIC TRIOXIDE is arsenic trioxide. There are five drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the arsenic trioxide profile page.
Summary for 208231
| Tradename: | ARSENIC TRIOXIDE |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | arsenic trioxide |
| Patents: | 0 |
Suppliers and Packaging for NDA: 208231
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ARSENIC TRIOXIDE | arsenic trioxide | INJECTABLE;INJECTION | 208231 | ANDA | Fresenius Kabi USA, LLC | 63323-637 | 63323-637-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-637-10) / 10 mL in 1 VIAL, SINGLE-DOSE (63323-637-03) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 1MG/ML | ||||
| Approval Date: | Aug 31, 2018 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
